Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wozniak, A. J.
Right arrow Articles by Livingston, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wozniak, A. J.
Right arrow Articles by Livingston, R. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 2459-2465, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

AJ Wozniak, JJ Crowley, SP Balcerzak, GR Weiss, CH Spiridonidis, LH Baker, KS Albain, K Kelly, SA Taylor, DR Gandara and RB Livingston
Wayne State University Medical Center, Detroit, MI, USA.

PURPOSE: Cisplatin has played a major role in the treatment of non- small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single- agent cisplatin in the treatment of patients with advanced NSCLC. METHODS: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function. RESULTS: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12% partial response rate. Arm II (cisplatin and vinorelbine) had a 26% response rate (2% complete responses and 24% partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20% for cisplatin alone and 36% for the combination arm. There was more hematologic toxicity on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar. CONCLUSION: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. H. Tan, J. Rolski, T. Grodzki, C. P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y. H. Tsai, et al.
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
Ann. Onc., July 1, 2009; 20(7): 1249 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Oncologist, May 1, 2009; 14(5): 497 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
J.-P. DELORD, C. PUOZZO, F. LEFRESNE, and R. BUGAT
Combination Chemotherapy of Vinorelbine and Cisplatin: A Phase I Pharmacokinetic Study in Patients with Metastatic Solid Tumors
Anticancer Res, February 1, 2009; 29(2): 553 - 560.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan
Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Ramlau, P. Zatloukal, J. Jassem, P. Schwarzenberger, S. V. Orlov, M. Gottfried, J. R. Pereira, G. Temperley, R. Negro-Vilar, S. Rahal, et al.
Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: SPIRIT I
J. Clin. Oncol., April 10, 2008; 26(11): 1886 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Edelman, D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, et al.
Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203
J. Clin. Oncol., February 20, 2008; 26(6): 848 - 855.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Ramalingam and C. Belani
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Oncologist, January 1, 2008; 13(suppl_1): 5 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Weiss, R Rosell, F Fossella, M Perry, R Stahel, F Barata, B Nguyen, S Paul, P McAndrews, N Hanna, et al.
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
Ann. Onc., March 1, 2007; 18(3): 453 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al.
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. N. Chhajed, F. Baty, M. Pless, S. Somandin, M. Tamm, and M. H. Brutsche
Outcome of Treated Advanced Non-small Cell Lung Cancer With and Without Central Airway Obstruction
Chest, December 1, 2006; 130(6): 1803 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, and M. J. Hawkins
Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
Ann. Onc., August 1, 2006; 17(8): 1263 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Auperin, C. Le Pechoux, J. P. Pignon, C. Koning, B. Jeremic, G. Clamon, L. Einhorn, D. Ball, M. G. Trovo, H. J. M. Groen, et al.
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients
Ann. Onc., March 1, 2006; 17(3): 473 - 483.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Yasuda, M. Yamaya, K. Nakayama, T. Sasaki, S. Ebihara, A. Kanda, M. Asada, D. Inoue, T. Suzuki, T. Okazaki, et al.
Randomized Phase II Trial Comparing Nitroglycerin Plus Vinorelbine and Cisplatin With Vinorelbine and Cisplatin Alone in Previously Untreated Stage IIIB/IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2006; 24(4): 688 - 694.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. K. Williamson, J. J. Crowley, P. N. Lara Jr, J. McCoy, D. H.M. Lau, R. W. Tucker, G. M. Mills, and D. R. Gandara
Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003
J. Clin. Oncol., December 20, 2005; 23(36): 9097 - 9104.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C.-L. Lai, C.-M. Tsai, C.-H. Chiu, G.-S. Wang, W.-J. Su, Y.-M. Chen, and R.-P. Perng
Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 700 - 706.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y.-M. Chen, R.-P. Perng, J.-F. Shih, C.-M. Tsai, and J. Whang-Peng
Chemotherapy for Non-small Cell Lung Cancer in Elderly Patients
Chest, July 1, 2005; 128(1): 132 - 139.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Platinums in Lung Cancer: Sufficient or Necessary?
J. Clin. Oncol., May 1, 2005; 23(13): 2882 - 2883.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J.-L. Pujol, J.-L. Breton, R. Gervais, P. Rebattu, A. Depierre, J.-F. Morere, B. Milleron, D. Debieuvre, D. Castera, P.-J. Souquet, et al.
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
Ann. Onc., April 1, 2005; 16(4): 602 - 610.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. Waechter, J. Passweg, M. Tamm, M. Brutsche, R. Herrmann, and M. Pless
Significant Progress in Palliative Treatment of Non-small Cell Lung Cancer in the Past Decade
Chest, March 1, 2005; 127(3): 738 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-Y. Douillard, R. Gervais, G. Dabouis, A. Le Groumellec, M. D'Arlhac, D. Spaeth, B. Coudert, D. Caillaud, A. Monnier, C. Clary, et al.
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
Ann. Onc., January 1, 2005; 16(1): 81 - 89.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. J. Stewart
Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer
Oncologist, December 1, 2004; 9(suppl_6): 43 - 52.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Morris, J. A. Blessing, B. J. Monk, R. McGehee, and D. H. Moore
Phase II Study of Cisplatin and Vinorelbine in Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
J. Clin. Oncol., August 15, 2004; 22(16): 3340 - 3344.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
JAMA, July 28, 2004; 292(4): 470 - 484.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. R. O'Brien, A. Szczesna, H. Karnicka, P. Zatloukal, T. Eisen, W. Hartmann, P. Kasan, B. Longerey, and F. Lefresne
Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study
Ann. Onc., June 1, 2004; 15(6): 921 - 927.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Iop, A. M. Manfredi, and S. Bonura
Fatigue in cancer patients receiving chemotherapy: an analysis of published studies
Ann. Onc., May 1, 2004; 15(5): 712 - 720.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Harper, T. Plunkett, and D. Khayat
In Reply:
J. Clin. Oncol., April 1, 2004; 22(7): 1347 - 1347.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. M. Mroz, A. Holownia, E. Chyczewska, L. Chyczewski, and J. J. Braszko
p53 N-Terminal Ser-15~P and Ser-20~P Levels in Squamous Cell Lung Cancer after Radio/Chemotherapy
Am. J. Respir. Cell Mol. Biol., April 1, 2004; 30(4): 564 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. Rocha Lima, N. A. Rizvi, C. Zhang, J. E. Herndon 2nd, J. Crawford, R. Govindan, G. W. King, and M. R. Green
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
Ann. Onc., March 1, 2004; 15(3): 410 - 418.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Spira and D. S. Ettinger
Multidisciplinary Management of Lung Cancer
N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392.
[Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 JCOHome page
K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, N. Katakami, T. Sugiura, M. Kawahara, A. Yokoyama, S. Yokota, et al.
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group
J. Clin. Oncol., January 15, 2004; 22(2): 254 - 261.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Unger, M. LeBlanc, J. J. Crowley, H. B. Grossman, R. B. Natale, A. J. Wozniak, J. R. Berenson, A. F. List, W. A. Peters III, R. C. Flanigan, et al.
Estimating the Impact of New Clinical Trial Proven Cancer Therapy and Cancer Chemoprevention on Population Mortality: The Karnofsky Memorial Lecture
J. Clin. Oncol., December 1, 2003; 21(90230): 246s - 252.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Jassem, P. Kosmidis, R. Ramlau, K. Zarogoulidis, L. Novakova, J. Breton, P.-L. Etienne, C. Seebacher, M. Grivaux, A. Ojala, et al.
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
Ann. Onc., November 1, 2003; 14(11): 1634 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. F. Smit, J. P.A.M. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, F. Schramel, H. Smit, R. Gaafar, B. Biesma, C. Manegold, et al.
Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975
J. Clin. Oncol., November 1, 2003; 21(21): 3909 - 3917.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-Y. Song, W. S. Kim, K. Kim, C. W. Jung, Y. H. Im, H. J. Kim, W. K. Kang, H. G. Lee, O J. Kwon, C. H. Rhee, et al.
Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 509 - 513.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Fossella, J. R. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, E. Kaukel, K. V. Mattson, R. Ramlau, A. Szczesna, P. Fidias, et al.
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group
J. Clin. Oncol., August 15, 2003; 21(16): 3016 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. S H Lam and R. J Ignoffo
A guide to clinically relevant drug interactions in oncology
Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85.
[Abstract] [PDF]

Home page
 Ann OncolHome page
A. M. Mauer, R. H. Ansari, P. C. Hoffman, S. A. Krauss, D. Taber, S. A. Tembe, G. T. Gabrys, T. Cotter, L. P. Schumm, L. Szeto, et al.
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer
Ann. Onc., May 1, 2003; 14(5): 722 - 728.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Freidlin, O. S. Breathnach, and B. E. Johnson
A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2003; 9(3): 917 - 922.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Kosmidis
In Reply:
J. Clin. Oncol., February 15, 2003; 21(4): 756 - 756.
[Full Text] [PDF]

Home page
 ChestHome page
M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer
Chest, January 1, 2003; 123 (2009): 226S - 243S.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. J. Souquet, E. H. Tan, J. Rodrigues Pereira, R. Van Klaveren, A. Price, U. Gatzemeier, M. Jaworski, J. P. Burillon, and D. Aubert
GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients
Ann. Onc., December 1, 2002; 13(12): 1853 - 1861.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla, et al.
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2002; 20(21): 4285 - 4291.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes, J. E. Herndon II, J. Crawford, K. A. Leopold, M. C. Perry, A. A. Miller, and M. R. Green
Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431
J. Clin. Oncol., October 15, 2002; 20(20): 4191 - 4198.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why?
J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Nottage and L. L. Siu
Principles of Clinical Trial Design
J. Clin. Oncol., September 15, 2002; 20(90001): 42s - 46.
[Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations
J. Clin. Oncol., September 1, 2002; 20(17): 3565 - 3567.
[Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, J. R. Gray, L. H. Morrissey, L. A. Kalman, J. K. Hon, and F. A. Greco
Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network
J. Clin. Oncol., July 1, 2002; 20(13): 2937 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Ettinger
Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-Small Cell Lung Cancer?
Oncologist, June 1, 2002; 7(3): 226 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. Monnet, H. d. Cremoux, P. Soulie, S. Saltiel-Voisin, M. Bekradda, J.-C. Saltiel, E. Brain, O. Rixe, Y. Yataghene, J.-L. Misset, et al.
Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study
Ann. Onc., January 19, 2002; 13(1): 103 - 107.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review
Thorax, January 1, 2002; 57(1): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Hotta, I. Sekine, T. Tamura, M. Sawada, H. Watanabe, H. Kusaba, Y. Akiyama, A. Inoue, T. Shimoyama, H. Nokihara, et al.
A Phase I/II Study of Cisplatin and Vinorelbine Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 596 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Fidias, J. G. Supko, R. Martins, A. Boral, R. Carey, M. Grossbard, G. Shapiro, P. Ostler, J. Lucca, B. E. Johnson, et al.
A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3942 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Inoue and N. Saijo
Recent Advances in the Chemotherapy of Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., July 1, 2001; 31(7): 299 - 304.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Kelly, J. Crowley, P. A. Bunn Jr, C. A. Presant, P. K. Grevstad, C. M. Moinpour, S. D. Ramsey, A. J. Wozniak, G. R. Weiss, D. F. Moore, et al.
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial
J. Clin. Oncol., July 1, 2001; 19(13): 3210 - 3218.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Khuri, J. R. Rigas, R. A. Figlin, R. J. Gralla, D. M. Shin, R. Munden, N. Fox, M. R. Huyghe, Y. Kean, S. D. Reich, et al.
Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 15, 2001; 19(10): 2626 - 2637.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. S. Breathnach, B. Freidlin, B. Conley, M. R. Green, D. H. Johnson, D. R. Gandara, M. O'Connell, F. A. Shepherd, and B. E. Johnson
Twenty-Two Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results
J. Clin. Oncol., March 15, 2001; 19(6): 1734 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Schuler, R. Herrmann, J. L.P. De Greve, A. K. Stewart, U. Gatzemeier, D. J. Stewart, L. Laufman, R. Gralla, J. Kuball, R. Buhl, et al.
Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study
J. Clin. Oncol., March 15, 2001; 19(6): 1750 - 1758.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, A. B. Sandler, L. L. Miller, P. K. Locker, C. K. Hanover, G. L. Elfring, V. K. Israel, N. Pirotta, and R. B. Natale
Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 15, 2001; 19(4): 1078 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Edelman
New Directions in the Treatment of Non-Small Cell Lung Cancer: An Overview
Oncologist, February 1, 2001; 6(2008): 1 - 3.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Masters
Carboplatin and Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
Oncologist, February 1, 2001; 6(2008): 12 - 15.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Lilenbaum
Options in Advanced Non-Small Cell Lung Cancer: A Review and Report on a Phase II Study of Vinorelbine Plus Gemcitabine
Oncologist, February 1, 2001; 6(2008): 16 - 19.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. E. Vokes
Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Non-Small Cell Lung Cancer
Oncologist, February 1, 2001; 6(2008): 25 - 27.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Monnet, P. Soulie, H. de Cremoux, S. Saltiel-Voisin, M. Bekradda, J.-C. Saltiel, E. Brain, G. Dupont-Andre, and E. Cvitkovic
Phase I/II Study of Escalating Doses of Vinorelbine in Combination With Oxaliplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 15, 2001; 19(2): 458 - 463.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al.
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585.
[Full Text] [PDF]

Home page
 JCOHome page
U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al.
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 19, 2000; 18(19): 3390 - 3399.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J.-Y. Han, K. W. Kim, J. A. Kim, J. H. Kang, J.-Y. Jin, Y. S. Hong, S. Y. Park, J.-S. Song, J. W. Park, H.-K. Kim, et al.
A Phase II Study of a Daily 4 Schedule of Vinorelbine Plus Cisplatin for Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., October 1, 2000; 30(10): 435 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, and P. A. Bunn Jr.
A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., September 1, 2000; 6(9): 3474 - 3479.
[Abstract] [Full Text]

Home page
 ChestHome page
Y.-M. Chen, R.-P. Perng, K.-Y. Yang, T.-W. Liu, C.-M. Tsai, J. Ming-Liu, and J. Whang-Peng
A Multicenter Phase II Trial of Vinorelbine Plus Gemcitabine in Previously Untreated Inoperable (Stage IIIB/IV) Non-small Cell Lung Cancer
Chest, June 1, 2000; 117(6): 1583 - 1589.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Comella, G. Frasci, N. Panza, L. Manzione, G. De Cataldis, R. Cioffi, L. Maiorino, E. Micillo, V. Lorusso, G. Di Rienzo, et al.
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
J. Clin. Oncol., April 7, 2000; 18(7): 1451 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. A. Bunn Jr. and K. Kelly
New Combinations in the Treatment of Lung Cancer : A Time for Optimism
Chest, April 1, 2000; 117 (2009): 138S - 143S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, D. Talbot, A. Rey, T. W. Butler, V. Hirsh, et al.
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
J. Clin. Oncol., March 13, 2000; 18(6): 1351 - 1359.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, Ch. Manegold, M. C. Palmer, A. Gregor, et al.
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 5, 2000; 18(1): 122 - 122.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. R. Gandara, E. Vokes, M. Green, P. Bonomi, R. Devore, R. Comis, D. Carbone, D. Karp, and C. Belani
Activity of Docetaxel in Platinum-Treated Non-Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial
J. Clin. Oncol., January 5, 2000; 18(1): 131 - 131.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Murray, R. B. Livingston, F. A. Shepherd, K. James, B. Zee, A. Langleben, M. Kraut, J. Bearden, J. W. Goodwin, C. Grafton, et al.
Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
J. Clin. Oncol., August 1, 1999; 17(8): 2300 - 2300.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Lynch Jr.
Lung Cancer Highlights
Oncologist, August 1, 1999; 4(4): 279 - 286.
[Full Text]

Home page
 JCOHome page
C. Sauter, A. J. Wozniak, and G. Giaccone
Chemotherapy of Advanced Non–Small-Cell Lung Cancer: ""Those Who Cannot Remember the Past Are Condemned to Repeat It""
J. Clin. Oncol., February 1, 1999; 17(2): 730 - 730.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online